VAGINACTIV Oral – Probiotic yeast S. cerevisiae CNCM I-3856, a new ingredient with proven efficacy on vaginal health

Over 75% of women worldwide experience at least one episode of vulvovaginal candidiasis in their life, with 6 to 8% of them suffering from recurrences (3 or more per year). Vulvovaginal candidiasis is the most prevalent cause of vaginal discomfort in women of reproductive age and is characterized by the disruption of the vaginal microbiota composition. This dysbiosis  thus favors Candida albicans overgrowth.

Focused on providing natural and effective solutions to people’s main health-related issues, and with over 160 years of experience in the yeast sector, Lesaffre Human Care was able to identify a unique probiotic yeast of particular interest for women’s health: VAGINACTIV Oral. This innovative probiotic is made of an exclusive and patented strain of Saccharomyces cerevisiae, registered as CNCM I-3856.

A new way for women to take care of their intimate health:

  • A recent study revealed the beneficial effects of VAGINACTIV Oral on the course of vaginal candidiasis:
    • Reduction of the occurrence and recurrence of C. albicans vaginal infections
    • Suppression of C. albicans virulence factors
    • Coaggregation of the yeast with the pathogen, thus promoting its elimination
    • Identification of a two-fold mechanism of action synergistically combining mechanical and biological actions for optimal efficacy
  • This study received attention from the scientific community with the recent publication of our scientific work in the journal Virulence1,2.

Additional benefits of using probiotic yeasts:

  • Safe & all-natural
  • No sensitivity to antibiotics
  • No yeast colonization of the intimate flora
  • Resistance to the exposure to the gastrointestinal tract

VAGINACTIV Oral could therefore be considered as safe and natural solution to be used concomitantly with conventional pharmaceutical treatments in order to help manage widespread vaginal mucosal infections and, on the long term, to prevent the recurrence of vulvovaginal candidiasis.

 

1 Pericolini E, Gabrielli E, Ballet N, Sabbatini S, Roselletti E, Cayzeele Decherf A, Pélerin F, Luciano E, Perito S, Justen P, Vecchiarelli A.Therapeutic activity of a Saccharomyces cerevisiae-based probiotic and inactivated whole yeast on vaginal candidiasis. Virulence. 2016 Jul 19:0. DOI: 10.1080/21505594.2016.1213937

2 Wilson D. A tale of two yeasts: Saccharomyces cerevisiae as a therapeutic against candidiasis. Virulence. 2016 Aug 31:0. DOI: 10.1080/21505594.2016.1230580

The information provided here is, to the best of our knowledge, true and accurate. However, our product must only be used in compliance with local laws and regulations. We cannot guarantee its freedom of use for every intended application or country.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Feel free to Contact Us for any commercial or technical information.